Researchers challenge genetic tests for guiding psychiatric treatment

May 23, 2018

In a paper published in JAMA Psychiatry, McLean Hospital's Program for Neuropsychiatric Research director Bruce M. Cohen, MD, PhD, and his colleagues, George S. Zubenko, MD, PhD, University of Pittsburgh School of Medicine (retired), and Barbara R.M. Sommer, MD, Stanford University School of Medicine, emerita, reviewed the scientific basis and effectiveness of pharmacogenetic (Pgen) tests in guiding the choices and doses of psychiatric medications for treating major depressive disorder (MDD) and related psychiatric conditions.

The paper, "On the Marketing and Use of Pharmacogenetic Tests for Psychiatric Treatment," comes at a time when a growing industry is vigorously marketing Pgen tests by claiming their results can improve the outcomes of patients with psychiatric disorders. According to the paper, one company website reported having already sold over 650,000 Pgen tests, with an estimated cost of $1 billion in genotyping and related clinical services.

As noted by Zubenko, the first author of the paper, "While the promise of Pgen-guided medication treatment of psychiatric disorders is appealing and supports the popular narrative of personalized/precision medicine, available evidence suggests that Pgen testing will not contribute much to improving care, if at all. And, in some cases, it could provide misleading information."

Citing the genomic evidence on psychiatric disorders, including MDD, the researchers raised questions about the likelihood that Pgen tests would predict either MDD or how patients will respond to treatment. This assessment arises from the very nature of the condition. As described in the paper, MDD is determined by a very large number of genes, and no single gene or limited gene set, even those for drug metabolism and drug targets, determine more than a few percent of the risk of illness or course of treatment, except in rare cases. Rather than genes, demographic and environmental factors, general health, clinical characteristics (psychiatric symptoms, severity, and comorbidity), and co-medication are usually much more important factors than inherited determinants of drug metabolism and response.

Moreover, the paper noted that while the activity of metabolic enzymes is heritable, extremely rapid or slow metabolism is rare, and dosing should be guided by careful dose choice and monitoring therapeutic and side effects rather than by Pgen test results. As for medication choice, the authors pointed out that there are standard evidence-based protocols to assist in clinical decision making.

The authors described multiple significant flaws in the design, implementation, and analysis of the 10 published effectiveness studies. Most studies evaluated by the authors were neither controlled nor blinded, and not a single paper was adequately blinded and properly controlled. In addition, the studies cited in marketing and promotional materials were funded by and included co-authors from the companies that offer Pgen services.

According to the authors, well-designed, controlled, and fully blinded studies are needed to determine whether expensive Pgen-guided care outperforms good care performed by board-certified psychiatrists using published protocols for the treatment of MDD. Efforts should also be made, they said, to minimize or eliminate financial and other conflicts of interest that may arise in the conduct of the studies and analysis of the results.

Zubenko emphasized that "doctors, patients, and family members should understand that the jury is out on whether Pgen testing improves good psychiatric care performed by board-certified psychiatrists." He further observed that "in a time of strained mental health care budgets, it's worth asking whether these federal and private healthcare dollars could be better spent on proven methods of care for patients with mental illnesses."

Cohen noted that "new technologies, when properly tested, should become part of clinical assessment, but Pgen has not passed such tests." He warned that "similar studies of inadequate design only add to the number of Pgen tests performed, not to the quality of the evidence on the value of those tests, and clinicians should be cautious in accepting claims until appropriate studies are performed."
-end-
McLean Hospital has a continuous commitment to put people first in innovation and discovery, patient care, and shared knowledge related to mental health. In 2017, it was named the #1 hospital for psychiatric care in the United States by U.S. News & World Report. McLean Hospital is the largest psychiatric affiliate of Harvard Medical School and a member of Partners HealthCare. For more information, please visit mcleanhospital.org or follow us on Facebook or Twitter.

McLean Hospital

Related Psychiatric Disorders Articles from Brightsurf:

Sexual minorities, especially women, who misuse substances more likely to have psychiatric disorders
More than half of lesbian, gay and bisexual individuals who misuse alcohol or tobacco also have a co-occurring psychiatric disorder, compared to one-third of heterosexuals, a new University of Michigan study finds.

Internet gaming youth not more prone to psychiatric disorders
Children who show addiction-like gaming signs are not any more susceptible to mental health problems than their non-gaming peers.

People with coronavirus symptoms more likely to have psychiatric disorders and loneliness
People who have or had COVID-19 symptoms are more likely to develop general psychiatric disorders and are lonelier, with women and young people more at risk, says a just-published study co-authored at Cambridge Judge Business School.

Brain structural elements in psychiatric disorders
While researchers have previously identified brain structural signatures associated with individual neurological diseases using techniques such as magnetic resonance imaging (MRI), a team of scientists based in Germany, in a new study, has compared data from multiple studies to find brain structural abnormalities shared between four different neuropsychiatric conditions.

Psychiatric disorders after first birth reduce likelihood of subsequent children
Women who suffer from psychiatric disorders such as depression, anxiety, mania and schizophrenia following the live birth of their first child are less likely to go on to have more children, according to the first study to investigate this in a large nationwide population.

International study completes the largest genetic map of psychiatric disorders so far
An international study published in the journal Cell, has described 109 genetic variants associated with eight psychiatric disorders: autism, ADHD, schizophrenia, bipolar disorder, depression, obsessive-compulsive disorder and Tourette Syndrome, in a total of about 230,000 patients worldwide.

Are there shared genetic factors between weight and major psychiatric disorders?
Data from 1.3 million people were used to investigate genetic overlap between body mass index and major psychiatric disorders such as schizophrenia, bipolar disorder and major depression.

How are psychiatric disorders linked to infections during pregnancy?
Severe infections during pregnancy have been connected to a range of psychiatric disorders by different studies in humans and animals.

Repeated febrile convulsions linked to epilepsy and psychiatric disorders
The risk of febrile convulsions increases with the child's fever, and children who suffer from repeated febrile convulsions during their first year of life have an increased risk of developing epilepsy and psychiatric disorders later in life.

Serum neurofilament is a discriminative biomarker between frontotemporal dementia and psychiatric disorders
Early symptoms of frontotemporal dementia are often confused with symptoms occurring in psychiatric disorders.

Read More: Psychiatric Disorders News and Psychiatric Disorders Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.